Senzime's Growth Dip Masks a Strategic Shift Toward Recurring Revenue

Senzime AB (publ) reported Q1 2026 results on April 22, and the headline was a rare miss: sales dipped 5% in the U.S. due to a slow start to hospital purchasing and a weak dollar. But inside the numbers, the company quietly accelerated its shift from capital equipment to a recurring-revenue model, landed a new pediatric guideline tailwind, and launched a connectivity platform that could open a new revenue line.

A Temporary Dip on a Growth Journey

CEO Philip Siberg was candid about the quarter: “Q1 2026 was a little bit of an outlier quarter. We reported a temporary dip on our growth journey, yet, at the same time, we reported strength in margins and good cash flow.” — Philip Siberg, CEO · 2026-04-22 The U.S. business grew 11% in local currency, but the strong Swedish krona and delayed monitor deals — many pushed into Q2 — cut reported sales. Crucially, sensor sales (the razorblade in this razor-razorblade business) grew 40% in constant currencies, and the company crossed the 1 million monitored patients milestone, a scale proof point for its installed base.

The dip is framed as timing, not loss: “I mean, like I said, it was an outlier, a little bit of kind of a onetime quarter... So we just saw a general – specifically in the U.S., that is like 60%, 70% of our business, which is pushed forward.” — Philip Siberg, CEO · 2026-04-22 That confidence is supported by a strong pipeline of order announcements in the weeks after the quarter.

Service Model Gains Traction

The most significant strategic development is the credit facility and the new TetraCom connectivity platform, but the real momentum story is TetraGraph-as-a-Service. Of the 246 TetraGraphs shipped in the U.S. during Q1, 120 went out under this model, where Senzime owns the monitors and charges a premium per sensor. The company closed deals with two Ivy League hospitals in about half the normal sales cycle. This model echoes the prior quarter's discussion—“So what we've introduced is a Tetragraph as a service business model. We then offer the monitors on a placement type of agreement. We get a premium pricing for the sensors...” — Philip Siberg, CEO · 2026-02-20—but now it's producing real numbers, and management expects it to drive utilization and margin long-term.

The market response has been positive:

So I think the response has been very positive, because even the hospitals know that contracting purposes or process can take over 2 years. So by doing this, by coming in, it just changes the opportunity to be more a standard operational.

Pediatric Guidelines and TetraCom: New Levers

A new European pediatric guideline explicitly recommends quantitative EMG monitoring for children, and Senzime is already seeing traction: sensor units tripled and 65 TetraGraphs were placed in pediatric ORs in Q1. The pediatric opportunity is small but growing fast, and it leverages the residual paralysis safety narrative.

Separately, TetraCom is a platform that wirelessly connects TetraGraph to Epic, Oracle, and other EHRs. It's sold under IT budgets (more elastic than capital purchases) and includes an annual service fee, adding another recurring revenue stream. Management expects meaningful contributions later this year.

These moves underscore a deliberate pivot from one-time monitor sales to a sticky, high-margin software-plus-services bundle, even as the U.S. market remains the primary growth engine.

Financial Positioning: Cash, Tariffs, and Targets

Senzime ended Q1 with SEK 55.3 million in cash and access to a SEK 50 million credit facility (SEK 7.5 million drawn). The company maintains its full-year growth and cash-flow-positive targets, citing improved underlying gross margin (69.2% vs. reported 63.1% after currency and tariffs) and strict OpEx control. The tariff overhang is real—they paid SEK 5 million in U.S. tariffs—but they're pursuing refunds and have raised U.S. prices by ~5%.

The prior quarter's message about not needing equity raises was reaffirmed: “And I've been clear to the market before that we're not expecting to do any rights issues or capital raises from equity rather we're funding this company now based on our customers...” — Philip Siberg, CEO · 2026-02-20 That stance, combined with a growing recurring base, suggests the burn rate is nearing an inflection.

While the Q1 dip is real, the strategic shifts—service model, pediatric guidelines, and TetraCom—position Senzime for a more predictable, asset‑light growth trajectory. The market's reaction to the report and subsequent order flow will tell whether the dip is truly a one-off or the start of a new cadence.